Juggling a mix of customer demand…
Juggling a mix of customer demand and new regulations, Recipharm [...]
AstraZeneca is showing no signs of…
AstraZeneca is showing no signs of restarting a 200 million [...]
As the Trump administration erodes…
As the Trump administration erodes U.S. infrastructure supporting infectious disease [...]
GLP-1 giant Eli Lilly has once…
GLP-1 giant Eli Lilly has once again taken to the [...]
The new chairman of the CDC’s…
The new chairman of the CDC’s Advisory Committee on Immunization [...]
ST Pharm has struck a $56 million…
ST Pharm has struck a $56 million deal with an [...]
A potential inflection point that…
A potential inflection point that Bausch Health hoped could diversify [...]
In the second week of oral…
In the second week of oral Wegovy’s launch, which ended [...]
¿Tu botiquín es un desastre?
Tener los medicamentos básicos adecuados puede facilitar el tratamiento de [...]
Plotting a challenge to…
Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has [...]